All News

lupus SLE

SLE Preview: abolishing refractory with CAR-T and better B-cell therapies

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.

Read Article
Risk Option Decision

The art of talking about risks with our patients

David Liew, FRACP

On the first day of EULAR 2024, I am debating Janet Pope.

Read Article
RheumNow Podcast square

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article
OA, erosive, inflammatory, DIP

2023 EULAR classification criteria for hand osteoarthritis

Jack Cush, MD

A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).

The criteria require two mandatory criteria to be met:

Read Article
CMS

ACR Calls on CMS for Enhanced Transparency & Reporting

Jack Cush, MD

The American College of Rheumatology has submitted its response to the Centers for Medicare & Medicaid Services (CMS) request for information and feedback from stakeholders on how best to enhance Medicare Advantage data capabilities and increase public transparency.

Read Article
RheumNow Podcast square

ACR’s Run at Goliath (PCPs) (5.31.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?

Read Article
Join us later for a some very exciting pieces of translational science across a AIRDs. All these abstracts sharing one thing in common: tissue, tissue, tissue! 16:30-18:00 Room A8.2 @RheumNow #EULAR2024 https://t.co/HrHP5tmHDD

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24

TheDaoIndex KDAO2011 ( View Tweet)

LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

#EULAR2024 Opening Ceremony. @DanielAletaha highlighted values of @eular strategies that have been achieved: Patient centredness ✔️ Innovation ✔️ - RheumaFacts, ENTRI, Exams Inclusivity ✔️ To strive on 3 other values by next year under President-Elect @XBaraliakos @RheumNow https://t.co/wDR2vtv3I2

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
📄 #EULARAdvocacy Chair @carmona_loreto discusses the @eular_org manifesto at the #EULAR2024 opening ceremony 🔗You can read the full manifesto and find out more here: https://t.co/6CZuSYpiLl @RheumNow https://t.co/DYcU9I6rmR

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
« We must work together to achieve a future where RMDs are no longer an invisible problem » Wise words from @carmona_loreto during Opening Plenary session #EULAR2024 @RheumNow

Aurelie Najm AurelieRheumo ( View Tweet)

2023 EULAR classification criteria for hand osteoarthritis A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA). https://t.co/wIgjYB2rXF https://t.co/TjSILyC4IT https://t.co/3x6YtXW81u

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Calls on CMS for Enhanced Transparency & Reporting The ACR has submitted its response to the CMS)request for information (RFI) and feedback from stakeholders on how best to enhance MA data capabilities and increase public transparency. https://t.co/vWPXlhmUGo https://t.co/Z8s3PZijqE

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM CASE- 46 yoM with Arthritis (wrists, ankles) and maculopapular Rash (chest, back, legs); prior travel to Caribbean, C. America, HTN, Tachycardia, ESR 104 , nl CRP, but ^d-dimer 990. Scattered alopecia & nasal crusting. Vote your Dx https://t.co/3bdmbnSdlB https://t.co/0R4WK1SKI2

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of 31 FDA Rheum drug approvals betw 1995-2021 showed patient-reported outcomes seldom reported or published. Despite meeting MCID (57%) & significance (85%), 1/3 PROs not reported & 10% remained unpublished (4yrs later) https://t.co/pvGhTxlP03 https://t.co/t3VEHw7FJv

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Gangsin: 갱신 Korean: refresh, renew, updated Over the last 20+ years, I have listened to patients confide their personal stories. Some remained paralyzed in their current state of distress, --I was one of them https://t.co/92tu3de4Ja https://t.co/ePGshN9t51 https://t.co/shdaov1ZPf

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits - Dx algorithm - Pathophys - Rx options - Alternative Rx https://t.co/epiP8Yi1Oz https://t.co/GsORbADJZy https://t.co/K7Q6Yrx1yI

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Website to Support PCPs The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for PCP and APP offering them expanded support and guidance to identify rheumatic diseases in their patients. https://t.co/yZbpG3598O https://t.co/S4oYNMrdqt

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×